New York

Psychedelic trials in New York

107 registered trials has a study site in New York, and 20 are recruiting now.

107

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
Neural Circuit Effects of Ketamine in DepressionNCT06213324 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 4	ketamine	1
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT07570654 · COMPASS Pathways	Recruiting	Phase 2 / Phase 3	psilocybin	1
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionNCT07716098 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	4
Nebulized Ketamine for the Treatment of Major Depressive DisorderNCT06752759 · Theresa Jacob, PhD, MPH	Recruiting	Phase 3	ketamine	1
Psilocybin Therapy in Advanced CancerNCT05398484 · NYU Langone Health	Recruiting	Phase 2 / Phase 3	psilocybin	2
Psilocybin-Assisted Therapy for Intergenerational TraumaNCT06899165 · Rachel Yehuda	Recruiting	Phase 2	psilocybin	1
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUDNCT06349083 · NYU Langone Health	Recruiting	Phase 2	psilocybin	1
Psilocybin to Treat Depression in Spinal Cord InjuryNCT07251491 · James J. Peters Veterans Affairs Medical Center	Recruiting	Phase 1 / Phase 2	psilocybin	1
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderNCT05452772 · Johns Hopkins University	Recruiting	Phase 2	psilocybin	3
A Phase 2A Trial of DT402 for Autism Spectrum DisorderNCT07303907 · Definium Therapeutics US, Inc.	Recruiting	Phase 2	mdma	1
Psilocybin for Opioid Use Disorder (OUD)NCT06796062 · NYU Langone Health	Recruiting	Phase 2	psilocybin	5
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of DepressionNCT06559826 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 2	ketamine	1
Dose Optimization of MDMA-Assisted Therapy for PTSDNCT06418178 · Bronx VA Medical Center	Recruiting	Phase 2	mdma	1
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderNCT06592833 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 2	psilocybin	1
Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsNCT07516405 · University of Colorado, Denver	Recruiting	Phase 1	psilocybin	6
MDMA Assisted Therapy for BNNCT07542145 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 1	mdma	1
MDMA-Assisted Therapy for Mental Healthcare ProvidersNCT07102576 · Rachel Yehuda	Recruiting	Phase 1	mdma	1
Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-LifeNCT06824532 · Albany Research Institute, Inc.	Recruiting	N/A	ketamine	1

Facilities

Where the research happens in New York

Facility	City	Trials
Icahn School of Medicine at Mount Sinai	New York	12
New York State Psychiatric Institute	New York	11
NYU Langone Health	New York	6
Mount Sinai School of Medicine	New York	5
Adams Clinical Harlem	New York	4
The Medical Research Network, LLC	New York	4
New York University	New York	4
Spectrum Neuroscience and Treatment Institute	New York	3
James J. Peters VA Medical Center	The Bronx	3
Maimonides Medical Center	Brooklyn	2
The Parsons Research Center for Psychedelic Healing	New York	2
Stratton VA Medical Center	Albany	2
Stony Brook University Medical Center	Stony Brook	2
New York State Psychiatric Institute/Columbia University	New York	2
Columbia University/New York State Psychiatric Institute	New York	2
Adams Clinical Bronx	The Bronx	2
Adams Clinical - New York	New York	2
New York Private Practice	New York	2
NYU Langone Medical Center/Tisch Hospital	New York	2
NY	New York	1
James J. Peters Department of Veterans Affairs Medical Center	The Bronx	1
StartCare	Brooklyn	1
VIP Community Services, Inc	The Bronx	1
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research	New York	1
New York University Langone Health, Center for Psychedelic Medicine	New York	1
Department of Psychiatry, Eating and Weight Disorders Program	New York	1
Weill Cornell Medicine	New York	1
Comprehensive Psychiatric Emergency Department of Columbia University Medical Center	New York	1
Clinilabs	New York	1
NYC Centre	New York	1
Zucker Hillside Hospital	Glen Oaks	1
Columbia University Adult and Late Life Depression Clinic	New York	1
Nathan Kline Institute for Psychiatric Research	Orangeburg	1
Montefiore Medical Center	The Bronx	1
The Brooklyn Hospital Center	Brooklyn	1
Dent Neurosciences Research Center, Inc.	Amherst	1
Fieve Clinical Research, Inc	New York	1
Richmond Behavioral Associates	Staten Island	1
Columbia - New York State Psychiatric Institute	New York	1
NYU Clinical & Translational Science Institute	New York	1

Stay told

When a trial opens in New York

All trials

Every trial with a New York site

Trial	Status	Phase	Substance	Sites
Neural Circuit Effects of Ketamine in DepressionNCT06213324 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 4	ketamine	1
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT07570654 · COMPASS Pathways	Recruiting	Phase 2 / Phase 3	psilocybin	1
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionNCT07716098 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	4
Nebulized Ketamine for the Treatment of Major Depressive DisorderNCT06752759 · Theresa Jacob, PhD, MPH	Recruiting	Phase 3	ketamine	1
Psilocybin Therapy in Advanced CancerNCT05398484 · NYU Langone Health	Recruiting	Phase 2 / Phase 3	psilocybin	2
Psilocybin-Assisted Therapy for Intergenerational TraumaNCT06899165 · Rachel Yehuda	Recruiting	Phase 2	psilocybin	1
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUDNCT06349083 · NYU Langone Health	Recruiting	Phase 2	psilocybin	1
Psilocybin to Treat Depression in Spinal Cord InjuryNCT07251491 · James J. Peters Veterans Affairs Medical Center	Recruiting	Phase 1 / Phase 2	psilocybin	1
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderNCT05452772 · Johns Hopkins University	Recruiting	Phase 2	psilocybin	3
A Phase 2A Trial of DT402 for Autism Spectrum DisorderNCT07303907 · Definium Therapeutics US, Inc.	Recruiting	Phase 2	mdma	1
Psilocybin for Opioid Use Disorder (OUD)NCT06796062 · NYU Langone Health	Recruiting	Phase 2	psilocybin	5
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of DepressionNCT06559826 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 2	ketamine	1
Dose Optimization of MDMA-Assisted Therapy for PTSDNCT06418178 · Bronx VA Medical Center	Recruiting	Phase 2	mdma	1
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderNCT06592833 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 2	psilocybin	1
Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsNCT07516405 · University of Colorado, Denver	Recruiting	Phase 1	psilocybin	6
MDMA Assisted Therapy for BNNCT07542145 · Icahn School of Medicine at Mount Sinai	Recruiting	Phase 1	mdma	1
MDMA-Assisted Therapy for Mental Healthcare ProvidersNCT07102576 · Rachel Yehuda	Recruiting	Phase 1	mdma	1
Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-LifeNCT06824532 · Albany Research Institute, Inc.	Recruiting	N/A	ketamine	1
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal ThoughtsNCT07139106 · New York State Psychiatric Institute	Not yet recruiting	Phase 4	ketamine	1
Biomarker-Guided Antidepressant SelectionNCT07680140 · Weill Medical College of Cornell University	Not yet recruiting	Phase 4	ketamine	1
IM Ketamine vs Midazolam for Suicidal ER PatientsNCT04640636 · New York State Psychiatric Institute	Suspended	Phase 4	ketamine	1
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for DepressionNCT05615948 · Theresa Jacob, PhD, MPH	Completed	Phase 4	ketamine	1
Comparative Effectiveness of ECT vs. KETAMINE Over the LifespanNCT06034821 · Brigham and Women's Hospital	Enrolling by invitation	Phase 4	ketamine	10
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental HealthNCT05604794 · Field Trip Health	Completed	Phase 4	ketamine	11
Ketamine Treatment Effects on Synaptic Plasticity in DepressionNCT04091971 · New York State Psychiatric Institute	Completed	Phase 4	ketamine	1
Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in DepressionNCT01881763 · Northwell Health	Completed	Phase 4	ketamine	1
Ketamine for Older Adults PilotNCT04504175 · Washington University School of Medicine	Completed	Phase 4	ketamine	5
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)NCT03149991 · Massachusetts General Hospital	Completed	Phase 4	ketamine	6
Ketamine in the Treatment of Suicidal DepressionNCT01700829 · New York State Psychiatric Institute	Completed	Phase 4	ketamine	1
Research Study for Major Depressive Disorder: Investigation of Glutamate MedicationsNCT00419003 · Baylor College of Medicine	Completed	Phase 4	ketamine	1
Ketamine v. Ketorolac for Management of Generalized Tension Type HeadacheNCT03221569 · The Brooklyn Hospital Center	Unknown status	Phase 4	ketamine	1
Treatment Study of Bipolar DepressionNCT00947791 · Icahn School of Medicine at Mount Sinai	Terminated	Phase 4	ketamine	1
Ketamine For Suicidal IdeationNCT01507181 · James Murrough	Completed	Phase 4	ketamine	1
NMDA Antagonists in Bipolar DepressionNCT01833897 · New York State Psychiatric Institute	Completed	Phase 4	ketamine	1
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL Limited	Active, not recruiting	Phase 3	psilocybin	45
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	22
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	34
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)NCT03537014 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	15
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)NCT04077437 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	14
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSDNCT04714359 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	15
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	61
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	30
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)NCT03113968 · Bo Hu	Completed	Phase 2 / Phase 3	ketamine	5
Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)NCT02397889 · Icahn School of Medicine at Mount Sinai	Completed	Phase 2 / Phase 3	ketamine	1
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal KetamineNCT04216888 · Dan Iosifescu	Completed	Phase 2 / Phase 3	ketamine	1
Study on the Use of Low Dose Ketamine After Gastric Bypass and GastrectomyNCT02452060 · NYU Langone Health	Completed	Phase 2 / Phase 3	ketamine	1
Intranasal Ketamine In the Treatment of Pediatric Bipolar DisorderNCT01504659 · Juvenile Bipolar Research Foundation	Terminated	Phase 2 / Phase 3	ketamine	4
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring OpioidsNCT06827054 · Roswell Park Cancer Institute	Not yet recruiting	Phase 2	psilocybin	1
Ketamine for Methamphetamine Use DisorderNCT06496750 · University of Texas Southwestern Medical Center	Active, not recruiting	Phase 2	ketamine	5
Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002NCT06816433 · Global Coalition for Adaptive Research	Suspended	Phase 2	ketamine	9
MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First RespondersNCT05455996 · Nautilus Sanctuary	Not yet recruiting	Phase 2	mdma	3
Ketamine-Assisted Psychotherapy for Treatment-Resistant DepressionNCT07247006 · University of Rochester	Not yet recruiting	Phase 2	ketamine	1
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · Usona Institute	Completed	Phase 2	psilocybin	11
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterNCT07296328 · NYU Langone Health	Not yet recruiting	Phase 2	psilocybin	1
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSDNCT04784143 · Resilient Pharmaceuticals	Terminated	Phase 2	mdma	1
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT05312151 · COMPASS Pathways	Completed	Phase 2	psilocybin	3
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSDNCT03282123 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	12
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	13
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	25
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	51
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive ImpairmentNCT06069843 · Icahn School of Medicine at Mount Sinai	Active, not recruiting	Phase 2	ketamine	1
Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSDNCT04889664 · Icahn School of Medicine at Mount Sinai	Completed	Phase 2	ketamine	1
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · Seelos Therapeutics, Inc.	Completed	Phase 2	ketamine	21
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200 · COMPASS Pathways	Completed	Phase 2	psilocybin	25
Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderNCT04656301 · New York State Psychiatric Institute	Completed	Phase 2	psilocybin	1
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol DependenceNCT02061293 · NYU Langone Health	Completed	Phase 2	psilocybin	2
Intramuscular Ketamine for Suicidal IdeationNCT05105061 · Icahn School of Medicine at Mount Sinai	Withdrawn	Phase 2	ketamine	1
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)NCT02422290 · New York State Psychiatric Institute	Completed	Phase 1 / Phase 2	ketamine	1
Ketamine and Nitroprusside for DepressionNCT03102736 · Icahn School of Medicine at Mount Sinai	Completed	Phase 2	ketamine	1
Ketamine for Suicidality in Bipolar DepressionNCT01944293 · New York State Psychiatric Institute	Completed	Phase 1 / Phase 2	ketamine	1
Ketamine in the Treatment of DepressionNCT01558063 · Columbia University	Completed	Phase 2	ketamine	1
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department PatientsNCT02106325 · NYU Langone Health	Completed	Phase 2	ketamine	2
Ketamine Plus Lithium in Treatment-Resistant DepressionNCT01880593 · Icahn School of Medicine at Mount Sinai	Completed	Phase 2	ketamine	1
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)NCT01920555 · Massachusetts General Hospital	Completed	Phase 2	ketamine	6
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)NCT00749203 · Dennis Charney	Completed	Phase 2	ketamine	1
Intravenous Ketamine in the Treatment of Obsessive-Compulsive DisorderNCT01371110 · Wayne Goodman MD	Terminated	Phase 1 / Phase 2	ketamine	1
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive DisorderNCT00956085 · New York State Psychiatric Institute	Completed	Phase 2	ketamine	1
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCDNCT02206776 · New York State Psychiatric Institute	Terminated	Phase 2	ketamine	1
Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)NCT01100255 · New York State Psychiatric Institute	Completed	Phase 2	ketamine	1
Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)NCT02062658 · New York State Psychiatric Institute	Completed	Phase 2	ketamine	1
Optimization of IV Ketamine for Treatment Resistant DepressionNCT00768430 · Baylor College of Medicine	Completed	Phase 2	ketamine	2
Psilocybin as a Novel Therapy for Residual AnhedoniaNCT07607938 · NYU Langone Health	Not yet recruiting	Phase 1	psilocybin	1
Ketamine Biomarker ValidationNCT07307768 · Soterix Medical	Not yet recruiting	Phase 1	ketamine	1
The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious ProfessionalsNCT02421263 · NYU Langone Health	Completed	Phase 1	psilocybin	1
The Role of HNKs in the Antidepressant Effect of KetamineNCT03977675 · Columbia University	Terminated	Phase 1	ketamine	1
Continuation Ketamine in Major DepressionNCT00548964 · James Murrough	Completed	Phase 1	ketamine	1
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)NCT06760533 · NYU Langone Health	Not yet recruiting	Early Phase 1	psilocybin	1
Intranasal Ketamine for Suicidal Ideation in VeteransNCT03788694 · Bronx Veterans Medical Research Foundation, Inc	Withdrawn	Early Phase 1	ketamine	1
Psilocybin Cancer Anxiety StudyNCT00957359 · NYU Langone Health	Completed	Early Phase 1	psilocybin	1
Perceptions of MDMA-Assisted Therapy Among Veterans With PTSDNCT05895318 · Albany Research Institute, Inc.	Completed	N/A	mdma	1
Entheogen ResurgenceNCT05042765 · Vireo Health	Completed	N/A	dmt	1
MRI Studies of Emotion in DepressionNCT02429011 · Icahn School of Medicine at Mount Sinai	Completed	N/A	ketamine	1
Intranasal Ketamine in Treatment-Resistant DepressionNCT01304147 · James Murrough	Completed	Not applicable	ketamine	1
Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in DepressionNCT01309581 · James Murrough	Terminated	Not applicable	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere